Acer Therapeutics: Funding, Investors & Team (Sep 2026)
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious rare, and life-threatening diseases with critical unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Acer Therapeutics has raised $49.5M across 2 funding rounds on record, the most recent an undisclosed round of $1.0M announced in Jun 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Acer Therapeutics Company Profile and Key Stats
Latest funding round on record: Jun 2023.
Acer Therapeutics Funding Rounds
Acer Therapeutics raised $48.5M in a Post-IPO Debt announced in Mar 2022.
1.3 years later, an undisclosed round of $1.0M was announced in Jun 2023.
Acer Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Acer Therapeutics Funding Compared to Other Biotechnology Startups
Acer Therapeutics' latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Acer Therapeutics in Biotechnology and Newton
Companies Similar to Acer Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Acer Therapeutics Funding FAQs
What does Acer Therapeutics do?
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious rare, and life-threatening diseases with critical unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO™ (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
How much funding has Acer Therapeutics raised?
Acer Therapeutics has raised $49.5M across 2 rounds on record. The most recent is an undisclosed round of $1.0M announced in Jun 2023.
When did Acer Therapeutics last raise funding?
Acer Therapeutics' most recent funding round on record is an undisclosed round of $1.0M, announced in Jun 2023.
Who founded Acer Therapeutics?
FundedIQ lists Chris Schelling (Founder) at Acer Therapeutics.
Where is Acer Therapeutics headquartered?
Acer Therapeutics is based in Newton, Massachusetts, United States.
How many employees does Acer Therapeutics have?
Acer Therapeutics is in the 11-50 employee band.
How does Acer Therapeutics' funding compare to other Biotechnology startups?
Acer Therapeutics' latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Acer Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Acer Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.